You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcebutolol
Accession NumberDB01193  (APRD00772)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. [PubChem]
Structure
Thumb
Synonyms
(+-)-Acebutolol
(±)-acebutolol
3'-acetyl-4'-(2-hydroxy-3-(isopropylamino)propoxy)butyranilide
5'-butyramido-2'-(2-hydroxy-3-isopropylaminopropoxy)acetophenone
Acebutolol
Acebutololum
Acetobutolol
N-(3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl)butanamide
N-[3-Acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]butanamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acebutololtablet200 mgoralSanis Health Inc2010-02-25Not applicableCanada
Acebutololtablet100 mgoralSanis Health Inc2010-02-25Not applicableCanada
Acebutololtablet400 mgoralSanis Health Inc2010-02-25Not applicableCanada
Acebutolol - 400 - Tab 400mgtablet400 mgoralPro Doc Limitee1996-12-31Not applicableCanada
Acebutolol-100-tab 100mgtablet100 mgoralPro Doc Limitee1996-12-31Not applicableCanada
Acebutolol-200 - Tab 200mgtablet200 mgoralPro Doc Limitee1996-12-31Not applicableCanada
Ava-acebutololtablet400 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-acebutololtablet100 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-acebutololtablet200 mgoralAvanstra Inc2011-10-112014-08-21Canada
Monitan 100tablet100 mgoralWyeth Canada1995-12-312004-09-13Canada
Monitan 200tablet200 mgoralWyeth Canada1995-12-312007-01-22Canada
Monitan 400tablet400 mgoralWyeth Canada1994-12-312007-01-22Canada
Monitan Tab 200mgtablet200 mgoralWyeth Ltd.1987-12-311996-09-10Canada
Monitan Tab 400mgtablet400 mgoralWyeth Ltd.1990-12-311996-09-10Canada
Mylan-acebutololtablet100 mgoralMylan Pharmaceuticals Ulc1998-04-06Not applicableCanada
Mylan-acebutololtablet200 mgoralMylan Pharmaceuticals Ulc1998-04-06Not applicableCanada
Mylan-acebutololtablet400 mgoralMylan Pharmaceuticals Ulc1998-04-06Not applicableCanada
Mylan-acebutolol (type S)tablet200 mgoralMylan Pharmaceuticals Ulc1998-09-16Not applicableCanada
Mylan-acebutolol (type S)tablet400 mgoralMylan Pharmaceuticals Ulc1998-09-16Not applicableCanada
Mylan-acebutolol (type S)tablet100 mgoralMylan Pharmaceuticals Ulc1998-09-16Not applicableCanada
Novo-acebutolol (type S)tablet400 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-acebutolol (type S)tablet100 mgoralNovopharm LimitedNot applicableNot applicableCanada
Novo-acebutolol (type S)tablet200 mgoralNovopharm LimitedNot applicableNot applicableCanada
Nu-acebutolol - Tab 100mgtablet100 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-acebutolol - Tab 200mgtablet200 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-acebutolol - Tab 400mgtablet400 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Penta-acebutolol Tabletstablet400 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-acebutolol Tabletstablet100 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Penta-acebutolol Tabletstablet200 mgoralPentapharm Ltd.Not applicableNot applicableCanada
Rhotral 100tablet100 mgoralSanofi Aventis Canada Inc1991-12-312010-10-26Canada
Rhotral 200tablet200 mgoralSanofi Aventis Canada Inc1991-12-312010-10-26Canada
Rhotral 400tablet400 mgoralSanofi Aventis Canada Inc1995-12-312011-01-06Canada
Sandoz Acebutololtablet400 mgoralSandoz Canada Incorporated2004-08-18Not applicableCanada
Sandoz Acebutololtablet100 mgoralSandoz Canada Incorporated2004-08-18Not applicableCanada
Sandoz Acebutololtablet200 mgoralSandoz Canada Incorporated2004-08-18Not applicableCanada
Sectralcapsule200 mg/1oralPromius Pharma, LLC1984-12-28Not applicableUs
Sectraltablet400 mgoralSanofi Aventis Canada Inc1990-12-31Not applicableCanada
Sectralcapsule400 mg/1oralPromius Pharma, LLC1984-12-28Not applicableUs
Sectraltablet100 mgoralSanofi Aventis Canada Inc1986-12-31Not applicableCanada
Sectraltablet200 mgoralSanofi Aventis Canada Inc1986-12-31Not applicableCanada
Teva-acebutololtablet100 mgoralTeva Canada Limited1996-08-16Not applicableCanada
Teva-acebutololtablet200 mgoralTeva Canada Limited1996-08-16Not applicableCanada
Teva-acebutololtablet400 mgoralTeva Canada Limited1996-08-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acebutolol Hydrochloridecapsule400 mg/1oralPhysicians Total Care, Inc.2005-04-22Not applicableUs
Acebutolol Hydrochloridecapsule200 mg/1oralMylan Pharmaceuticals Inc.1995-04-24Not applicableUs
Acebutolol Hydrochloridecapsule400 mg/1oralAv Kare, Inc.2009-12-14Not applicableUs
Acebutolol Hydrochloridecapsule200 mg/1oralbryant ranch prepack2009-12-01Not applicableUs
Acebutolol Hydrochloridecapsule400 mg/1oralMylan Pharmaceuticals Inc.1995-04-24Not applicableUs
Acebutolol Hydrochloridecapsule200 mg/1oralAv Pak2009-12-01Not applicableUs
Acebutolol Hydrochloridecapsule200 mg/1oralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Acebutolol Hydrochloridecapsule200 mg/1oralMajor Pharmaceuticals2009-12-01Not applicableUs
Acebutolol Hydrochloridecapsule400 mg/1oralAv Pak2009-12-01Not applicableUs
Acebutolol Hydrochloridecapsule400 mg/1oralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Acebutolol Hydrochloridecapsule200 mg/1oralAv Kare, Inc.2009-12-14Not applicableUs
Apo-acebutololtablet100 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-acebutololtablet200 mgoralApotex Inc1995-12-31Not applicableCanada
Apo-acebutololtablet400 mgoralApotex Inc1995-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PrentBayer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Acebutolol Hydrochloride
34381-68-5
Thumb
  • InChI Key:
  • Monoisotopic Mass:
  • Average Mass:
DBSALT000192
Categories
UNII67P356D8GH
CAS number37517-30-9
WeightAverage: 336.4259
Monoisotopic: 336.204907394
Chemical FormulaC18H28N2O4
InChI KeyInChIKey=GOEMGAFJFRBGGG-UHFFFAOYSA-N
InChI
InChI=1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
IUPAC Name
N-(3-acetyl-4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)butanamide
SMILES
CCCC(=O)NC1=CC(C(C)=O)=C(OCC(O)CNC(C)C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylamides. These are organic compounds that contain a carboxamide group that is N-linked to a aryl group. They have the generic structure RC(=O)N(R')H, R = organyl group and R'= aryl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassN-arylamides
Sub ClassNot Available
Direct ParentN-arylamides
Alternative Parents
Substituents
  • N-arylamide
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Fatty amide
  • Monocyclic benzene moiety
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Ketone
  • Carboxamide group
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the management of hypertension and ventricular premature beats in adults.
PharmacodynamicsAcebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. In general, beta-blockers reduce the work the heart has to do and allow it to beat more regularly. Acebutolol has less antagonistic effects on peripheral vascular ß2-receptors at rest and after epinephrine stimulation than nonselective beta-antagonists. Low doses of acebutolol produce less evidence of bronchoconstriction than nonselective agents like propranolol but more than atenolol.
Mechanism of actionAcebutolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Acebutolol blocks these receptors, lowering the heart rate and blood pressure. This drug then has the reverse effect of epinephrine. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels.
Related Articles
AbsorptionWell absorbed from the Gl tract with an absolute bioavailability of approximately 40% for the parent compound. In
Volume of distributionNot Available
Protein binding26%
Metabolism

Subject to extensive first-pass hepatic biotransformation (primarily to diacetolol).

Route of eliminationElimination via renal excretion is approximately 30% to 40% and by non-renal mechanisms 50% to 60%, which includes excretion into the bile and direct passage through the intestinal wall.
Half lifeThe plasma elimination half-life is approximately 3 to 4 hours. The half-life of its metabolite, diacetolol, is 8 to 13 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include extreme bradycardia, advanced atrioventricular block, intraventricular conduction defects, hypotension, severe congestive heart failure, seizures, and in susceptible patients, bronchospasm, and hypoglycemia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Acebutolol Action PathwayDrug actionSMP00296
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.7378
P-glycoprotein inhibitor INon-inhibitor0.8557
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterNon-inhibitor0.9466
CYP450 2C9 substrateNon-substrate0.8102
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5752
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8721
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9639
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.849
BiodegradationNot ready biodegradable0.8538
Rat acute toxicity2.0487 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9821
hERG inhibition (predictor II)Non-inhibitor0.8555
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral200 mg/1
Capsuleoral400 mg/1
Tabletoral100 mg
Tabletoral200 mg
Tabletoral400 mg
Prices
Unit descriptionCostUnit
Acebutolol hcl powder7.08USD g
Sectral 400 mg capsule4.48USD capsule
Sectral 200 mg capsule3.37USD capsule
Acebutolol HCl 400 mg capsule1.39USD capsule
Acebutolol 400 mg capsule1.34USD capsule
Sectral 400 mg Tablet1.11USD tablet
Acebutolol HCl 200 mg capsule1.05USD capsule
Acebutolol 200 mg capsule1.01USD capsule
Sectral 200 mg Tablet0.56USD tablet
Acebutolol 400 mg Tablet0.51USD tablet
Apo-Acebutolol 400 mg Tablet0.51USD tablet
Mylan-Acebutolol (Type S) 400 mg Tablet0.51USD tablet
Mylan-Acebutolol 400 mg Tablet0.51USD tablet
Novo-Acebutolol 400 mg Tablet0.51USD tablet
Nu-Acebutolol 400 mg Tablet0.51USD tablet
Rhotral 400 mg Tablet0.51USD tablet
Sectral 100 mg Tablet0.37USD tablet
Acebutolol 200 mg Tablet0.26USD tablet
Apo-Acebutolol 200 mg Tablet0.26USD tablet
Mylan-Acebutolol (Type S) 200 mg Tablet0.26USD tablet
Mylan-Acebutolol 200 mg Tablet0.26USD tablet
Novo-Acebutolol 200 mg Tablet0.26USD tablet
Nu-Acebutolol 200 mg Tablet0.26USD tablet
Rhotral 200 mg Tablet0.26USD tablet
Acebutolol 100 mg Tablet0.17USD tablet
Apo-Acebutolol 100 mg Tablet0.17USD tablet
Mylan-Acebutolol (Type S) 100 mg Tablet0.17USD tablet
Mylan-Acebutolol 100 mg Tablet0.17USD tablet
Novo-Acebutolol 100 mg Tablet0.17USD tablet
Nu-Acebutolol 100 mg Tablet0.17USD tablet
Rhotral 100 mg Tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point136-138Merck Index 13
water solubility259 mg/LNot Available
logP1.71HANSCH,C ET AL. (1995)
Caco2 permeability-5.83ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.172 mg/mLALOGPS
logP1.43ALOGPS
logP1.53ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)13.91ChemAxon
pKa (Strongest Basic)9.57ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area87.66 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity94.87 m3·mol-1ChemAxon
Polarizability38.51 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US3857952
General ReferencesNot Available
External Links
ATC CodesC07AB04C07BB04
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Acebutolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Acebutolol.
AcepromazineAcepromazine may increase the hypotensive activities of Acebutolol.
AcetaminophenThe serum concentration of Acebutolol can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Acebutolol.
AcetohexamideAcebutolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Acetylcholine.
AcetyldigitoxinAcebutolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Acebutolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Acebutolol.
AfatinibThe serum concentration of Acebutolol can be increased when it is combined with Afatinib.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Acebutolol.
AlbendazoleThe serum concentration of Acebutolol can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.
AldosteroneThe serum concentration of Acebutolol can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Acebutolol can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Acebutolol can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Acebutolol.
AlfuzosinAcebutolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Acebutolol.
AliskirenAcebutolol may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Acebutolol.
AmantadineThe serum concentration of Acebutolol can be increased when it is combined with Amantadine.
AmbenoniumAmbenonium may increase the bradycardic activities of Acebutolol.
AmbrisentanAcebutolol may increase the hypotensive activities of Ambrisentan.
AmifostineAcebutolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Acebutolol.
Aminohippuric acidThe serum concentration of Acebutolol can be increased when it is combined with Aminohippuric acid.
AminophyllineAcebutolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Acebutolol.
AmitriptylineThe serum concentration of Acebutolol can be increased when it is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Acebutolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Acebutolol.
AmodiaquineThe metabolism of Acebutolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Acebutolol can be increased when it is combined with Amoxapine.
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Acebutolol.
AmprenavirThe serum concentration of Acebutolol can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Acebutolol can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Acebutolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Acebutolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Acebutolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Acebutolol.
ApremilastApremilast may decrease the antihypertensive activities of Acebutolol.
ArbutamineAcebutolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Arecoline.
ArformoterolAcebutolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Acebutolol.
AripiprazoleAripiprazole may increase the hypotensive activities of Acebutolol.
AstemizoleThe serum concentration of Acebutolol can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Acebutolol can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Acebutolol.
AtomoxetineAtomoxetine may increase the hypertensive activities of Acebutolol.
AtorvastatinThe serum concentration of Acebutolol can be increased when it is combined with Atorvastatin.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Acebutolol.
AzelastineAzelastine may decrease the antihypertensive activities of Acebutolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Acebutolol can be increased when it is combined with Azithromycin.
BalsalazideBalsalazide may decrease the antihypertensive activities of Acebutolol.
BambuterolAcebutolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Acebutolol.
BenazeprilBenazepril may increase the hypotensive activities of Acebutolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Acebutolol.
BenmoxinBenmoxin may increase the hypotensive activities of Acebutolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Acebutolol.
BenzocaineThe serum concentration of Acebutolol can be increased when it is combined with Benzocaine.
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Acebutolol.
BepridilAcebutolol may increase the hypotensive activities of Bepridil.
BeractantAcebutolol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Acebutolol.
BethanecholThe risk or severity of adverse effects can be increased when Acebutolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Acebutolol.
BimatoprostBimatoprost may increase the hypotensive activities of Acebutolol.
BiperidenThe serum concentration of Acebutolol can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Acebutolol.
BosentanBosentan may increase the hypotensive activities of Acebutolol.
BosutinibThe serum concentration of Acebutolol can be increased when it is combined with Bosutinib.
BretyliumBretylium may increase the bradycardic activities of Acebutolol.
BretyliumAcebutolol may increase the hypotensive activities of Bretylium.
BrimonidineAcebutolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Acebutolol.
BromfenacBromfenac may decrease the antihypertensive activities of Acebutolol.
BromocriptineAcebutolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineThe serum concentration of Acebutolol can be increased when it is combined with Bromocriptine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Acebutolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Acebutolol.
BupranololAcebutolol may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Acebutolol can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Acebutolol can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Acebutolol can be increased when it is combined with Cabazitaxel.
CabergolineAcebutolol may increase the vasoconstricting activities of Cabergoline.
CaffeineThe serum concentration of Acebutolol can be increased when it is combined with Caffeine.
CalfactantAcebutolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Acebutolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Acebutolol.
CaptoprilAcebutolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Acebutolol is combined with Carbachol.
CarbamazepineThe serum concentration of Acebutolol can be decreased when it is combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Acebutolol.
CarprofenCarprofen may decrease the antihypertensive activities of Acebutolol.
CarteololCarteolol may increase the hypotensive activities of Acebutolol.
CarvedilolCarvedilol may increase the hypotensive activities of Acebutolol.
CaspofunginThe serum concentration of Acebutolol can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may decrease the antihypertensive activities of Acebutolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Acebutolol.
CeliprololAcebutolol may increase the hypotensive activities of Celiprolol.
CeritinibAcebutolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Acebutolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Acebutolol.
ChlorphentermineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Chlorphentermine.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Acebutolol.
ChlorpropamideAcebutolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Acebutolol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Acebutolol can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Acebutolol.
CholesterolThe serum concentration of Acebutolol can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Acebutolol can be decreased when it is combined with Cholic Acid.
CilazaprilAcebutolol may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Acebutolol can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Acebutolol can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Acebutolol can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Acebutolol can be increased when it is combined with Clarithromycin.
ClenbuterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.
ClofazimineThe serum concentration of Acebutolol can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Acebutolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Acebutolol.
ClonixinClonixin may decrease the antihypertensive activities of Acebutolol.
ClotrimazoleThe serum concentration of Acebutolol can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Acebutolol can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Acebutolol can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Acebutolol can be increased when it is combined with Colforsin.
CoumaphosCoumaphos may increase the bradycardic activities of Acebutolol.
CrizotinibThe serum concentration of Acebutolol can be increased when it is combined with Crizotinib.
CrizotinibAcebutolol may increase the bradycardic activities of Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Acebutolol.
CyclophosphamideThe serum concentration of Acebutolol can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Acebutolol can be decreased when it is combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Acebutolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Acebutolol.
DaclatasvirThe serum concentration of Acebutolol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Acebutolol can be increased when it is combined with Dactinomycin.
DapagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Acebutolol can be increased when it is combined with Dapoxetine.
DasatinibThe serum concentration of Acebutolol can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Acebutolol can be decreased when it is combined with Daunorubicin.
DebrisoquinAcebutolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Acebutolol.
DemecariumDemecarium may increase the bradycardic activities of Acebutolol.
DeserpidineAcebutolol may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Acebutolol can be increased when it is combined with Desipramine.
DeslanosideAcebutolol may increase the bradycardic activities of Deslanoside.
DesloratadineThe serum concentration of Acebutolol can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Acebutolol can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Acebutolol.
DextromethorphanThe serum concentration of Acebutolol can be increased when it is combined with Dextromethorphan.
DiazoxideDiazoxide may increase the hypotensive activities of Acebutolol.
DichlorvosDichlorvos may increase the bradycardic activities of Acebutolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Acebutolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Acebutolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Acebutolol.
DigitoxinAcebutolol may increase the bradycardic activities of Digitoxin.
DigoxinAcebutolol may increase the bradycardic activities of Digoxin.
DigoxinThe serum concentration of Acebutolol can be decreased when it is combined with Digoxin.
DihydroergotamineAcebutolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineThe serum concentration of Acebutolol can be increased when it is combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Acebutolol.
DinutuximabThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Acebutolol.
DipivefrinAcebutolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Acebutolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Acebutolol.
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Acebutolol.
DonepezilDonepezil may increase the bradycardic activities of Acebutolol.
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Acebutolol.
DorzolamideDorzolamide may increase the hypotensive activities of Acebutolol.
DoxazosinDoxazosin may increase the hypotensive activities of Acebutolol.
DoxepinThe serum concentration of Acebutolol can be increased when it is combined with Doxepin.
DoxofyllineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Doxofylline.
DoxorubicinThe serum concentration of Acebutolol can be decreased when it is combined with Doxorubicin.
DronabinolDronabinol may increase the tachycardic activities of Acebutolol.
DronedaroneThe serum concentration of Acebutolol can be increased when it is combined with Dronedarone.
DronedaroneAcebutolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Acebutolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Acebutolol.
DroxidopaAcebutolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineAcebutolol may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineAcebutolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Acebutolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Acebutolol.
EfonidipineAcebutolol may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Acebutolol can be increased when it is combined with Elbasvir.
EmpagliflozinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Acebutolol.
EnalaprilatAcebutolol may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Acebutolol can be increased when it is combined with Enzalutamide.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Acebutolol.
EphedraAcebutolol may decrease the bronchodilatory activities of Ephedra.
EphedrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Ephedrine.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Acebutolol is combined with EPIBATIDINE.
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Acebutolol.
EpirizoleEpirizole may decrease the antihypertensive activities of Acebutolol.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Acebutolol.
EpoprostenolAcebutolol may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Acebutolol.
Ergoloid mesylateAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineAcebutolol may increase the vasoconstricting activities of Ergonovine.
ErgonovineThe serum concentration of Acebutolol can be increased when it is combined with Ergonovine.
ErgotamineAcebutolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineThe serum concentration of Acebutolol can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Acebutolol can be decreased when it is combined with Erythromycin.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Acebutolol.
EstramustineThe serum concentration of Acebutolol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Acebutolol can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Acebutolol can be decreased when it is combined with Estrone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Acebutolol.
EtilefrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Etilefrine.
EtodolacEtodolac may decrease the antihypertensive activities of Acebutolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Acebutolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.
EtoperidoneThe serum concentration of Acebutolol can be increased when it is combined with Etoperidone.
EtoposideThe serum concentration of Acebutolol can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Acebutolol.
EtravirineThe serum concentration of Acebutolol can be increased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Acebutolol.
exisulindexisulind may decrease the antihypertensive activities of Acebutolol.
FelodipineFelodipine may increase the hypotensive activities of Acebutolol.
FenbufenFenbufen may decrease the antihypertensive activities of Acebutolol.
FenfluramineThe serum concentration of Acebutolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Acebutolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Acebutolol.
FenoterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Fenoterol.
FentanylThe serum concentration of Acebutolol can be increased when it is combined with Fentanyl.
FenthionFenthion may increase the bradycardic activities of Acebutolol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Acebutolol.
FexofenadineThe serum concentration of Acebutolol can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Acebutolol can be increased when it is combined with Fidaxomicin.
FingolimodAcebutolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Acebutolol.
FluconazoleThe serum concentration of Acebutolol can be increased when it is combined with Fluconazole.
FlunixinFlunixin may decrease the antihypertensive activities of Acebutolol.
FluoxetineThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Acebutolol can be increased when it is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Acebutolol.
FlurazepamThe serum concentration of Acebutolol can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Acebutolol.
FluvoxamineThe serum concentration of Acebutolol can be increased when it is combined with Fluvoxamine.
FormoterolAcebutolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Acebutolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Acebutolol.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Acebutolol.
GalantamineGalantamine may increase the bradycardic activities of Acebutolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Acebutolol.
GefitinibThe serum concentration of Acebutolol can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Acebutolol can be increased when it is combined with Genistein.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Acebutolol.
GlibornurideAcebutolol may increase the hypoglycemic activities of Glibornuride.
GliclazideAcebutolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideAcebutolol may increase the hypoglycemic activities of Glimepiride.
GlipizideAcebutolol may increase the hypoglycemic activities of Glipizide.
GliquidoneAcebutolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideAcebutolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideAcebutolol may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Acebutolol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Acebutolol can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Acebutolol can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Acebutolol can be increased when it is combined with Grepafloxacin.
GTS-21The risk or severity of adverse effects can be increased when Acebutolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Acebutolol.
GuanadrelGuanadrel may increase the hypotensive activities of Acebutolol.
GuanethidineGuanethidine may increase the hypotensive activities of Acebutolol.
GuanfacineGuanfacine may increase the hypotensive activities of Acebutolol.
HaloperidolThe serum concentration of Acebutolol can be increased when it is combined with Haloperidol.
HexamethoniumAcebutolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Acebutolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Acebutolol.
Huperzine AHuperzine A may increase the bradycardic activities of Acebutolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Acebutolol.
HydralazineAcebutolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Acebutolol.
HydrocortisoneThe serum concentration of Acebutolol can be increased when it is combined with Hydrocortisone.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Acebutolol.
Hydroxyamphetamine hydrobromideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe metabolism of Acebutolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Acebutolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Acebutolol.
IcatibantIcatibant may decrease the antihypertensive activities of Acebutolol.
IdelalisibThe serum concentration of Acebutolol can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Acebutolol.
ImatinibThe serum concentration of Acebutolol can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Acebutolol can be increased when it is combined with Imipramine.
IndacaterolAcebutolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Acebutolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Acebutolol.
IndenololAcebutolol may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Acebutolol can be decreased when it is combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Acebutolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Acebutolol.
IndoraminAcebutolol may increase the hypotensive activities of Indoramin.
Insulin PorkAcebutolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Acebutolol.
IproniazidIproniazid may increase the hypotensive activities of Acebutolol.
IrbesartanIrbesartan may increase the hypotensive activities of Acebutolol.
IsavuconazoniumThe serum concentration of Acebutolol can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Acebutolol.
IsoetarineAcebutolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Acebutolol.
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Acebutolol.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Acebutolol.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol.
IsoxicamIsoxicam may decrease the antihypertensive activities of Acebutolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Acebutolol.
ItraconazoleThe serum concentration of Acebutolol can be increased when it is combined with Itraconazole.
IvabradineAcebutolol may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Acebutolol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Acebutolol can be increased when it is combined with Ivermectin.
KebuzoneKebuzone may decrease the antihypertensive activities of Acebutolol.
KetamineThe serum concentration of Acebutolol can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Acebutolol can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Acebutolol.
KetorolacKetorolac may decrease the antihypertensive activities of Acebutolol.
LabetalolLabetalol may increase the hypotensive activities of Acebutolol.
LacidipineAcebutolol may increase the hypotensive activities of Lacidipine.
LacosamideAcebutolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideAcebutolol may increase the bradycardic activities of Lanreotide.
LansoprazoleThe serum concentration of Acebutolol can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Acebutolol can be increased when it is combined with Lapatinib.
LatanoprostLatanoprost may increase the hypotensive activities of Acebutolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Acebutolol.
LercanidipineLercanidipine may increase the hypotensive activities of Acebutolol.
LevobunololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Levobunolol.
LevodopaAcebutolol may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Acebutolol can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Acebutolol can be increased when it is combined with Levomilnacipran.
LevothyroxineThe serum concentration of Acebutolol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Acebutolol.
LinezolidLinezolid may increase the hypertensive activities of Acebutolol.
LiothyronineThe serum concentration of Acebutolol can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Acebutolol can be decreased when it is combined with Liotrix.
LisinoprilLisinopril may increase the hypotensive activities of Acebutolol.
LobelineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Lobeline.
LofexidineAcebutolol may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Acebutolol can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Acebutolol can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Acebutolol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Acebutolol can be increased when it is combined with Loratadine.
LornoxicamLornoxicam may decrease the antihypertensive activities of Acebutolol.
LosartanLosartan may increase the hypotensive activities of Acebutolol.
LovastatinThe serum concentration of Acebutolol can be increased when it is combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Acebutolol.
Lu AA21004The serum concentration of Acebutolol can be increased when it is combined with Lu AA21004.
LucinactantAcebutolol may increase the bradycardic activities of Lucinactant.
LumacaftorThe serum concentration of Acebutolol can be decreased when it is combined with Lumacaftor.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Acebutolol.
MacitentanAcebutolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Acebutolol.
MalathionMalathion may increase the bradycardic activities of Acebutolol.
ManidipineAcebutolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Acebutolol.
MaprotilineThe serum concentration of Acebutolol can be increased when it is combined with Maprotiline.
MasoprocolMasoprocol may decrease the antihypertensive activities of Acebutolol.
MebanazineMebanazine may increase the hypotensive activities of Acebutolol.
MebendazoleThe serum concentration of Acebutolol can be increased when it is combined with Mebendazole.
MecamylamineMecamylamine may increase the hypotensive activities of Acebutolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Acebutolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Acebutolol.
MefloquineMefloquine may increase the bradycardic activities of Acebutolol.
Megestrol acetateThe serum concentration of Acebutolol can be increased when it is combined with Megestrol acetate.
MeloxicamMeloxicam may decrease the antihypertensive activities of Acebutolol.
MemantineMemantine may increase the bradycardic activities of Acebutolol.
MephentermineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.
MeprobamateThe serum concentration of Acebutolol can be increased when it is combined with Meprobamate.
MesalazineMesalazine may decrease the antihypertensive activities of Acebutolol.
MesoridazineMesoridazine may increase the hypotensive activities of Acebutolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Acebutolol.
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Acebutolol.
MethacholineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Methacholine.
MethadoneThe serum concentration of Acebutolol can be increased when it is combined with Methadone.
MethamphetamineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Methamphetamine.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Acebutolol.
MethohexitalMethohexital may increase the hypotensive activities of Acebutolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Acebutolol.
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Acebutolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acebutolol.
MethyldopaMethyldopa may increase the hypotensive activities of Acebutolol.
Methylene blueMethylene blue may increase the hypotensive activities of Acebutolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Acebutolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Acebutolol.
MetipranololAcebutolol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Acebutolol.
MetoprololMetoprolol may increase the hypotensive activities of Acebutolol.
MibefradilAcebutolol may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Acebutolol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Acebutolol can be decreased when it is combined with Midazolam.
MidodrineAcebutolol may increase the bradycardic activities of Midodrine.
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Acebutolol.
MifepristoneThe serum concentration of Acebutolol can be decreased when it is combined with Mifepristone.
MilnacipranThe serum concentration of Acebutolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Acebutolol.
MinoxidilMinoxidil may increase the hypotensive activities of Acebutolol.
MitomycinThe serum concentration of Acebutolol can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Acebutolol can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the hypotensive activities of Acebutolol.
MoexiprilMoexipril may increase the hypotensive activities of Acebutolol.
MolsidomineMolsidomine may increase the hypotensive activities of Acebutolol.
MoricizineMoricizine may increase the hypotensive activities of Acebutolol.
MorphineThe serum concentration of Acebutolol can be increased when it is combined with Morphine.
MoxonidineAcebutolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Acebutolol.
NabiloneNabilone may increase the tachycardic activities of Acebutolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Acebutolol.
NadololAcebutolol may increase the hypotensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Acebutolol.
NaltrexoneThe serum concentration of Acebutolol can be increased when it is combined with Naltrexone.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Acebutolol.
NaproxenNaproxen may decrease the antihypertensive activities of Acebutolol.
NaringeninThe serum concentration of Acebutolol can be increased when it is combined with Naringenin.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Acebutolol.
NebivololAcebutolol may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Acebutolol can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Acebutolol can be decreased when it is combined with Nelfinavir.
NeostigmineNeostigmine may increase the bradycardic activities of Acebutolol.
NepafenacNepafenac may decrease the antihypertensive activities of Acebutolol.
NesiritideThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Acebutolol.
NicardipineNicardipine may increase the hypotensive activities of Acebutolol.
NicorandilNicorandil may increase the hypotensive activities of Acebutolol.
NicotineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Acebutolol.
NifedipineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Acebutolol.
NiguldipineAcebutolol may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Acebutolol can be increased when it is combined with Nilotinib.
NilvadipineAcebutolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Acebutolol.
NimodipineNimodipine may increase the hypotensive activities of Acebutolol.
NisoldipineNisoldipine may increase the hypotensive activities of Acebutolol.
NitrazepamThe serum concentration of Acebutolol can be increased when it is combined with Nitrazepam.
NitrendipineNitrendipine may increase the hypotensive activities of Acebutolol.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Acebutolol.
NitroprussideNitroprusside may increase the hypotensive activities of Acebutolol.
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Acebutolol.
NorethisteroneThe serum concentration of Acebutolol can be decreased when it is combined with Norethisterone.
NylidrinThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nylidrin.
ObinutuzumabAcebutolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Acebutolol.
OctreotideOctreotide may increase the bradycardic activities of Acebutolol.
OlanzapineThe serum concentration of Acebutolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Acebutolol.
OlodaterolAcebutolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Acebutolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Acebutolol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Acebutolol.
OmeprazoleThe serum concentration of Acebutolol can be increased when it is combined with Omeprazole.
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Acebutolol.
OrgoteinOrgotein may decrease the antihypertensive activities of Acebutolol.
OuabainAcebutolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Acebutolol.
OxprenololAcebutolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Acebutolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Acebutolol.
P-NitrophenolThe serum concentration of Acebutolol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Acebutolol can be increased when it is combined with Paclitaxel.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.
Palmitic AcidThe serum concentration of Acebutolol can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Acebutolol can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Acebutolol.
PargylineAcebutolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Acebutolol can be increased when it is combined with Paroxetine.
PasireotideAcebutolol may increase the bradycardic activities of Pasireotide.
PenbutololAcebutolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Acebutolol.
PentoliniumPentolinium may increase the hypotensive activities of Acebutolol.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Acebutolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Acebutolol.
PerindoprilPerindopril may increase the hypotensive activities of Acebutolol.
PerphenazinePerphenazine may increase the hypotensive activities of Acebutolol.
PhenelzinePhenelzine may increase the hypotensive activities of Acebutolol.
PheniprazinePheniprazine may increase the hypotensive activities of Acebutolol.
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Acebutolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Acebutolol.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Acebutolol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Acebutolol.
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Acebutolol.
PhentolaminePhentolamine may increase the hypotensive activities of Acebutolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Acebutolol.
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Acebutolol.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Acebutolol.
PhysostigminePhysostigmine may increase the bradycardic activities of Acebutolol.
PilocarpineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Acebutolol.
PimozideThe serum concentration of Acebutolol can be increased when it is combined with Pimozide.
PinacidilAcebutolol may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Acebutolol.
PirbuterolAcebutolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Acebutolol.
PirlindolePirlindole may increase the hypotensive activities of Acebutolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Acebutolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Acebutolol.
Platelet Activating FactorThe serum concentration of Acebutolol can be decreased when it is combined with Platelet Activating Factor.
PolythiazideAcebutolol may increase the hypotensive activities of Polythiazide.
PonatinibThe serum concentration of Acebutolol can be increased when it is combined with Ponatinib.
Poractant alfaAcebutolol may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Acebutolol can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Acebutolol can be increased when it is combined with Pravastatin.
PrazosinPrazosin may increase the hypotensive activities of Acebutolol.
PrednisoneThe serum concentration of Acebutolol can be increased when it is combined with Prednisone.
PrimaquineThe metabolism of Acebutolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Acebutolol.
ProbenecidThe serum concentration of Acebutolol can be increased when it is combined with Probenecid.
ProcaterolThe risk or severity of adverse effects can be increased when Acebutolol is combined with Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Acebutolol.
ProgesteroneThe serum concentration of Acebutolol can be decreased when it is combined with Progesterone.
PromazinePromazine may increase the hypotensive activities of Acebutolol.
PromethazinePromethazine may increase the hypotensive activities of Acebutolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Acebutolol.
PropafenoneThe serum concentration of Acebutolol can be increased when it is combined with Propafenone.
PropafenoneAcebutolol may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Acebutolol.
ProtriptylineThe serum concentration of Acebutolol can be increased when it is combined with Protriptyline.
PseudoephedrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Pseudoephedrine.
PTC299PTC299 may decrease the antihypertensive activities of Acebutolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Acebutolol.
QuercetinThe serum concentration of Acebutolol can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Quetiapine.
QuinacrineThe serum concentration of Acebutolol can be increased when it is combined with Quinacrine.
QuinaprilQuinapril may increase the hypotensive activities of Acebutolol.
QuinidineThe serum concentration of Acebutolol can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Acebutolol.
RacepinephrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Racepinephrine.
RamiprilRamipril may increase the hypotensive activities of Acebutolol.
RanitidineThe serum concentration of Acebutolol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Acebutolol can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Acebutolol.
ReboxetineThe serum concentration of Acebutolol can be increased when it is combined with Reboxetine.
RegorafenibRegorafenib may increase the bradycardic activities of Acebutolol.
RemikirenRemikiren may increase the hypotensive activities of Acebutolol.
RescinnamineAcebutolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Acebutolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Acebutolol.
RifampicinThe serum concentration of Acebutolol can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Acebutolol can be increased when it is combined with Rilpivirine.
RiociguatAcebutolol may increase the hypotensive activities of Riociguat.
RisperidoneAcebutolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Acebutolol.
RitonavirThe serum concentration of Acebutolol can be decreased when it is combined with Ritonavir.
RituximabAcebutolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Acebutolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Acebutolol.
RolapitantThe serum concentration of Acebutolol can be increased when it is combined with Rolapitant.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Acebutolol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Acebutolol.
SafrazineSafrazine may increase the hypotensive activities of Acebutolol.
SalbutamolAcebutolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Acebutolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Acebutolol.
SalmeterolAcebutolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Acebutolol.
SaprisartanAcebutolol may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Acebutolol can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Acebutolol can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Acebutolol.
SelegilineSelegiline may increase the hypotensive activities of Acebutolol.
SelexipagAcebutolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Acebutolol.
SertralineThe serum concentration of Acebutolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Acebutolol.
SilodosinAcebutolol may increase the orthostatic hypotensive activities of Silodosin.
SimeprevirThe serum concentration of Acebutolol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Acebutolol can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Acebutolol can be decreased when it is combined with Sirolimus.
SitaxentanAcebutolol may increase the hypotensive activities of Sitaxentan.
SorafenibThe serum concentration of Acebutolol can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Acebutolol.
SpiraprilAcebutolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.
SRT501SRT501 may decrease the antihypertensive activities of Acebutolol.
St. John's WortThe serum concentration of Acebutolol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Acebutolol can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Acebutolol can be decreased when it is combined with Streptozocin.
SufentanilSufentanil may increase the bradycardic activities of Acebutolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Acebutolol.
SulfinpyrazoneThe serum concentration of Acebutolol can be increased when it is combined with Sulfinpyrazone.
SulindacSulindac may decrease the antihypertensive activities of Acebutolol.
SumatriptanThe serum concentration of Acebutolol can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Acebutolol can be increased when it is combined with Sunitinib.
SuprofenSuprofen may decrease the antihypertensive activities of Acebutolol.
SynephrineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Synephrine.
TacrineTacrine may increase the bradycardic activities of Acebutolol.
TacrolimusThe serum concentration of Acebutolol can be decreased when it is combined with Tacrolimus.
TadalafilTadalafil may increase the antihypertensive activities of Acebutolol.
TamoxifenThe serum concentration of Acebutolol can be decreased when it is combined with Tamoxifen.
TamsulosinAcebutolol may increase the orthostatic hypotensive activities of Tamsulosin.
Taurocholic AcidThe serum concentration of Acebutolol can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Acebutolol.
TelmisartanTelmisartan may increase the hypotensive activities of Acebutolol.
TemocaprilAcebutolol may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Acebutolol can be increased when it is combined with Temsirolimus.
TenoxicamTenoxicam may decrease the antihypertensive activities of Acebutolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Acebutolol.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Acebutolol.
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Acebutolol.
TerfenadineThe serum concentration of Acebutolol can be increased when it is combined with Terfenadine.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Acebutolol.
TerlipressinAcebutolol may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Acebutolol can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Acebutolol can be increased when it is combined with Testosterone.
TetryzolineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tetryzoline.
TheophyllineAcebutolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Acebutolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Acebutolol.
ThiopentalThiopental may increase the hypotensive activities of Acebutolol.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Acebutolol.
ThioridazineThioridazine may increase the hypotensive activities of Acebutolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.
TiboloneAcebutolol may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Acebutolol can be increased when it is combined with Ticagrelor.
TicrynafenAcebutolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Acebutolol.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Acebutolol.
TofacitinibTofacitinib may increase the bradycardic activities of Acebutolol.
TolazamideAcebutolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Acebutolol.
TolbutamideAcebutolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Acebutolol.
TolmetinTolmetin may decrease the antihypertensive activities of Acebutolol.
ToloxatoneToloxatone may increase the hypotensive activities of Acebutolol.
TolvaptanThe serum concentration of Acebutolol can be increased when it is combined with Tolvaptan.
TorasemideTorasemide may increase the hypotensive activities of Acebutolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Acebutolol.
TranilastTranilast may decrease the antihypertensive activities of Acebutolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Acebutolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Acebutolol.
TravoprostTravoprost may increase the hypotensive activities of Acebutolol.
TrazodoneThe serum concentration of Acebutolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Acebutolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Acebutolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Acebutolol.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Acebutolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Acebutolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Acebutolol.
TrimazosinAcebutolol may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Acebutolol.
TrimethoprimThe serum concentration of Acebutolol can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Acebutolol can be increased when it is combined with Trimipramine.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Acebutolol.
TroleandomycinThe serum concentration of Acebutolol can be increased when it is combined with Troleandomycin.
TubocurarineTubocurarine may increase the bradycardic activities of Acebutolol.
TyramineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Tyramine.
UdenafilUdenafil may increase the antihypertensive activities of Acebutolol.
UnoprostoneAcebutolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Acebutolol.
ValsartanValsartan may increase the hypotensive activities of Acebutolol.
VardenafilVardenafil may increase the antihypertensive activities of Acebutolol.
VareniclineThe risk or severity of adverse effects can be increased when Acebutolol is combined with Varenicline.
VenlafaxineThe serum concentration of Acebutolol can be increased when it is combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Acebutolol.
VilanterolAcebutolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Acebutolol can be increased when it is combined with Vilazodone.
VinblastineThe serum concentration of Acebutolol can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Acebutolol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Acebutolol can be increased when it is combined with Vinorelbine.
VortioxetineThe serum concentration of Acebutolol can be increased when it is combined with Vortioxetine.
XylometazolineAcebutolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Acebutolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Acebutolol.
ZileutonZileuton may decrease the antihypertensive activities of Acebutolol.
ZimelidineThe serum concentration of Acebutolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Acebutolol.
Food Interactions
  • Take without regard to meals; absorption rate and maximal concentration are slightly reduced but the extent of absorption is not affected.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. van den Meiracker AH, Man in 't Veld AJ, Fischberg DJ, Molinoff PB, van Eck HJ, Boomsma F, Derkx FH, Schalekamp MA: Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density. J Cardiovasc Pharmacol. 1988 Apr;11(4):413-23. [PubMed:2453744 ]
  2. Abrahamsson T: Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70. Eur J Pharmacol. 1989 May 2;164(1):121-8. [PubMed:2568935 ]
  3. Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
partial agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Fraysse B, Garric J: Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. [PubMed:16268148 ]
  2. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  3. Lima JJ: Relationship between beta adrenoceptor occupancy and receptor down-regulation induced by beta antagonists with intrinsic sympathomimetic activity. J Recept Signal Transduct Res. 1996 Sep-Nov;16(5-6):357-72. [PubMed:8968966 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  2. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23